STAT Plus: CytoDyn is in financial and clinical distress, newly filed annual report shows
An annual report disclosed by CytoDyn on Friday night describes a drug maker in distress. It’s a more troubling summary of CytoDyn’s current situation than the boom times described by company executives in innumerable press releases, conference calls, and YouTube videos.
CytoDyn’s financial losses are growing and its balance sheet is deteriorating, according to the year-end report, also known as a 10-K, filed with the Securities and Exchange Commission. Cytodyn’s fiscal year ended on May 31.
